Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Dec 4, 2020
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Purchase
Common Stock
[F1]2020-11-30$4.75/sh+52,632$250,002→ 52,632 total(indirect: By Sino-American Cancer FDD) - Purchase
Warrants to Purchase Common Stock
[F1]2020-11-30$4.75/sh+52,632$250,002→ 52,632 total(indirect: By Sino-American Cancer FDD)Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (52,632 underlying)
Holdings
- 16,666
Options to Purchase Common Stock
Exercise: $1.68From: 2018-08-04Exp: 2023-08-04→ Common (16,666 underlying) - 16,667
Options to Purchase Common Stock
Exercise: $1.68From: 2019-08-04Exp: 2024-08-04→ Common (16,667 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying)
Footnotes (1)
- [F1]The reporting person acquired 52,632 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.
Signature
/s/ Sino=American Cancer FDD /s/ Yun Yen|2020-12-02